Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
06:04a PFIZER : U.S. pharmaceutical firms to extend investments in Egypt
08/18 PFIZER : Global Anal Fistula Treatment Market 2022 - Teva, Novartis, Pfizer, Roc..
08/18 PFIZER : Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the..
08/18 PFIZER : Receives U.S. FDA Approval F=for Besponsa (Inotuzumab Ozogamicin)
08/18 BRISTOL-MYERS SQUIBB AND PFIZER : to Highlight Commitment to Reducing the Risk o..
08/18 PFIZER : Receives u.s. fda approval for besponsa
08/17 PFIZER : FDA OKs Pfizer drug for rare, fast-killing type of leukemia
08/17 PFIZER : Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)
08/17 FINDINGS FROM PFIZER IN PHARMACOLOGY : Clinical Pharmacology Perspectives)
08/17 PFIZER : Lessening the Burden of Non-Communicable Diseases
More news
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 52 721 M
EBIT 2017 19 844 M
Net income 2017 11 415 M
Debt 2017 23 771 M
Yield 2017 3,93%
P/E ratio 2017 17,44
P/E ratio 2018 15,13
EV / Sales 2017 4,14x
EV / Sales 2018 3,98x
Capitalization 194 554 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,5 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC194 554
JOHNSON & JOHNSON15.12%357 079
ROCHE HOLDING LTD.4.99%218 752
NOVARTIS8.84%218 545
PFIZER0.59%196 221
MERCK AND COMPANY4.45%168 660